文献速递衰弱、肌少症与跌倒多重用药老年综合评估

衰弱与多重用药对老年人健康结局的影响:FRADEA研究

Frailty, Polypharmacy, and Health Outcomes in Older Adults: The Frailty and Dependence in Albacete Study.
PubMed 文献 · J Am Med Dir Assoc · 2017-09-09

FRADEA队列研究纳入773名70岁以上西班牙老年人,按衰弱表型和多重用药(慢性使用≥5种药物)分为6组,随访5.5年。结果显示,衰弱合并多重用药者死亡或新发日常生活活动能力残疾的调整OR为5.3(95%CI 2.3-12.5),住院OR为2.3(95%CI 1.2-4.4);衰弱和衰弱前期合并多重用药者死亡风险分别升高(HR 5.8,95%CI 1.9-17.5;HR 3.1,95%CI 1.1-9.1),非衰弱者中多重用药与不良结局无关。

要点

  • 衰弱合并多重用药者死亡或残疾风险显著升高(OR 5.3)。
  • 衰弱和衰弱前期合并多重用药者死亡风险均升高。
  • 非衰弱老年人中多重用药与不良结局无关。

核心结论

  • 多重用药与衰弱和衰弱前期老年人的死亡、新发残疾、住院和急诊就诊相关,但在非衰弱老年人中无此关联。
  • 建议对衰弱和衰弱前期老年患者监测多重用药以优化健康结局。

研究设计与样本

  • 正在进行的队列研究,纳入西班牙Albacete市FRADEA研究中773名70岁以上参与者,其中女性457名(59.1%)。
  • 基线收集衰弱表型、多重用药(慢性使用5种或更多药物)和共病,按衰弱与多重用药分为6组,随访5.5年(平均1057天,范围1-2007天)。

主要发现

  • 研究人群平均年龄78.5岁。
  • 各组分布:衰弱合并多重用药15.3%(n=118),衰弱无多重用药3.4%(n=26),衰弱前期合并多重用药35.3%(n=273),衰弱前期无多重用药20.3%(n=157),非衰弱合并多重用药10.3%(n=80),非衰弱无多重用药15.4%(n=119)。
  • 与非衰弱无多重用药者相比,衰弱合并多重用药者死亡或新发日常生活活动能力残疾的调整OR为5.3(95%CI 2.3-12.5),住院OR为2.3(95%CI 1.2-4.4)。
  • 与非衰弱无多重用药者相比,衰弱合并多重用药者死亡风险HR为5.8(95%CI 1.9-17.5),衰弱前期合并多重用药者HR为3.1(95%CI 1.1-9.1)。

关键数值与推荐

  • 多重用药定义为慢性使用5种或更多药物。
  • 衰弱状态采用衰弱表型评估。
  • 主要结局为死亡或新发日常生活活动能力残疾,同时记录住院和急诊就诊。

临床怎么用

  • 对衰弱和衰弱前期的老年患者,应常规评估并监测多重用药。
  • 多重用药可作为衰弱老年人不良结局的风险标志,需综合管理以优化健康结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: To investigate if polypharmacy modifies the association between frailty and health outcomes in older adults. DESIGN: Ongoing cohort study. SETTING: Albacete City, Spain. PARTICIPANTS: A total for 773 participants, 457 women (59.1%), over age 70 years from the FRADEA Study. MEASUREMENTS: Frailty phenotype, polypharmacy considered as the chronic use of 5 or more drugs, and comorbidity were collected at the baseline visit. Participants were categorized in 6 groups according to frailty and polypharmacy, and were followed up for 5.5 years (mean 1057 days, range 1-2007). Mortality or incident disability in basic activities of daily living was considered the main outcome variable. Hospitalization and visits to the emergency department were also recorded. The adjusted association between combined frailty status and polypharmacy with outcome variables was analyzed. RESULTS: The mean age of study population was 78.5 years. In this population, we identified a 15.3% (n = 118) of frail with polypharmacy, 3.4% (n = 26) of frail without polypharmacy, 35.3% (n = 273) of prefrail with polypharmacy, 20.3% (n = 157) of prefrail without polypharmacy, 10.3% (n = 80) of nonfrail with polypharmacy, and 15.4% (n = 119) of nonfrail participants without polypharmacy. Participants with frailty and polypharmacy had a higher adjusted risk of mortality or incident disability [odds ratio (OR) 5.3; 95% confidence interval (CI) 2.3-12.5] and hospitalization (OR 2.3; 95% CI 1.2-4.4), compared with those without frailty and polypharmacy. Frail and prefrail participants with polypharmacy had a higher adjusted mortality risk compared with the nonfrail without polypharmacy, hazard ratio 5.8 (95% CI 1.9-17.5) and hazard ratio 3.1 (95% CI 1.1-9.1), respectively. CONCLUSIONS: Polypharmacy is associated with mortality, incident disability, hospitalization, and emergency department visits in frail and prefrail older adults, but not in nonfrail adults. Polypharmacy should be monitored in these patient subgroups to optimize health outcomes.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Bonaga B, Sánchez-Jurado PM, Martínez-Reig M, et al. Frailty, Polypharmacy, and Health Outcomes in Older Adults: The Frailty and Dependence in Albacete Study. J Am Med Dir Assoc. 2017. PMID: 28899661. doi:10.1016/j.jamda.2017.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。